| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Laboratoire de Génétique, UMR 5641 CNRS, UCBL1, and
* Laboratoire de Biologie de la Reproduction et du Développement, UCBL1, 69373 Lyon cedex 08, France
1Correspondence: Laboratoire de Génétique, UMR 5641 CNRS, Domaine Rockefeller, UCBL1, 8 avenue Rockefeller, 69373 Lyon cedex 08, France. E-mail: dante{at}cismsun.univ-lyon1.fr
In mammalians, demethylation of specific promoter regions often correlates with gene activation; inversely, dense methylation of CpG islands leads to gene silencing, probably mediated by methyl-CpG binding proteins. In cell lines and cancers, inhibition of tissue-specific genes and tumor suppressor genes expression seems to be related to such hypermethylation. The 5' end of the breast cancer predisposition gene BRCA1 is embedded in a large CpG island of ~2.7 kb in length. In human sporadic breast cancers, the down-regulation of BRCA1 does not seem to be related to BRCA1 gene alterations. Southern blot analysis and the bisulfite sequencing method indicate that the BRCA1 CpG island is regionally methylated in all human tissues analyzed and unmethylated in the gametes, suggesting a role for DNA methylation in the control of gene expression. We have therefore investigated the potential role of methyl-CpG binding proteins in the regulation of BRCA1 gene expression. In vitro, partial methylation of constructs containing this region strongly inhibits gene expression in the presence of MeCP2 protein. Moreover, in the five human cell lines analyzed, chemically induced hypomethylation is associated with BRCA1 gene activation. These data suggest that methyl-CpG binding proteins might be associated with the control of BRCA1 gene expression and that methyl-DNA binding proteins may participate in the regulation of gene expression in mammalian cells.—Magdinier, F., Billard, L.-M., Wittmann, G., Frappart, L., Benchaïb, M., Lenoir, G. M., Guérin, J. F., Dante, R. Regional methylation of the 5' end CpG island of BRCA1 is associated with reduced gene expression in human somatic cells.
Key Words: DNA methylation • oocytes • spermatozoa • breast cancer
This article has been cited by other articles:
|
|
 |
|
  C. Jordan and U. Francke Ube3a expression is not altered in Mecp2 mutant mice Hum. Mol. Genet., July 15, 2006; 15(14): 2210 - 2215. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Wei, T. A. Grushko, J. Dignam, F. Hagos, R. Nanda, L. Sveen, J. Xu, J. Fackenthal, M. Tretiakova, S. Das, et al. BRCA1 Promoter Methylation in Sporadic Breast Cancer Is Associated with Reduced BRCA1 Copy Number and Chromosome 17 Aneusomy Cancer Res., December 1, 2005; 65(23): 10692 - 10699. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Auriol, L.-M. Billard, F. Magdinier, and R. Dante Specific binding of the methyl binding domain protein 2 at the BRCA1-NBR2 locus Nucleic Acids Res., July 28, 2005; 33(13): 4243 - 4254. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Thakur, T. Nakamura, G. Calin, A. Russo, J. F. Tamburrino, M. Shimizu, G. Baldassarre, S. Battista, A. Fusco, R. P. Wassell, et al. Regulation of BRCA1 Transcription by Specific Single-Stranded DNA Binding Factors Mol. Cell. Biol., June 1, 2003; 23(11): 3774 - 3787. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. WEI, R. BROWN, and T. H.-M. HUANG Aberrant DNA Methylation in Ovarian Cancer: Is There an Epigenetic Predisposition to Drug Response? Ann. N.Y. Acad. Sci., March 1, 2003; 983(1): 243 - 250. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. El-Osta, M. Lubbert, P. W. Wijermans, T. Licht, and P. A. Jones On the use of DNA methylation inhibitors and the reversal of transcriptional silencing Blood, February 15, 2003; 101(4): 1656 - 1657. [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Hilton, J. P. Geisler, J. A. Rathe, M. A. Hattermann-Zogg, B. DeYoung, and R. E. Buller Inactivation of BRCA1 and BRCA2 in Ovarian Cancer J Natl Cancer Inst, September 18, 2002; 94(18): 1396 - 1406. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Roder, M.-J. Latasa, and H. S. Sul Silencing of the Mouse H-rev107 Gene Encoding a Class II Tumor Suppressor by CpG Methylation J. Biol. Chem., August 16, 2002; 277(34): 30543 - 30550. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Magdinier, S. G. d'Estaing, C. Peinado, B. Demirci, C. Berthet, J. F. Guerin, and R. Dante Epigenetic marks at BRCA1 and p53 coding sequences in early human embryogenesis Mol. Hum. Reprod., July 1, 2002; 8(7): 630 - 635. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Ballestar and M. Esteller The impact of chromatin in human cancer: linking DNA methylation to gene silencing Carcinogenesis, July 1, 2002; 23(7): 1103 - 1109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. D. Braastad, M. Leguia, and E. A. Hendrickson Ku86 autoantigen related protein-1 transcription initiates from a CpG island and is induced by p53 through a nearby p53 response element Nucleic Acids Res., April 15, 2002; 30(8): 1713 - 1724. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. D. Jeffy, R. B. Chirnomas, E. J. Chen, J. M. Gudas, and D. F. Romagnolo Activation of the Aromatic Hydrocarbon Receptor Pathway Is Not Sufficient for Transcriptional Repression of BRCA-1: Requirements for Metabolism of Benzo[a]pyrene to 7r,8t-Dihydroxy-9t,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene Cancer Res., January 1, 2002; 62(1): 113 - 121. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Magdinier and A. P. Wolffe Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia PNAS, April 12, 2001; (2001) 101617298. [Abstract] [Full Text]
|
|
|
|
|
|
F. Magdinier and A. P. Wolffe Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia PNAS, April 24, 2001; 98(9): 4990 - 4995. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
